Participated · Series H · May 2026

Anthropic is a premier artificial intelligence safety and research company renowned for developing Claude, a family of highly capable, steerable, and safe large language models. Founded by former OpenAI researchers, Anthropic pioneers techniques like "Constitutional AI" to build systems that are helpful, honest, and harmless. Beyond its core research, the company has rapidly scaled into a dominant market force, experiencing exponential revenue growth driven by widespread enterprise adoption. Anthropic has attracted unprecedented investor attention, recently raising approximately $30 billion at a $380 billion valuation, with ongoing negotiations potentially boosting its valuation to roughly $800 billion. As a leading competitor in the generative AI space, the company is reportedly exploring an IPO later this year.

Led · Seed · Sep 2025

Isotopes offers Aidnn, an AI agent designed to find, extract, clean, normalize and join data from wherever it is stored (finance apps, ERP, CRM, cloud storage, Salesforce, Snowflake) so non-technical business users can query it in natural language. The agent maintains contextual memory for complex, multistep tasks, displays its steps, reasoning and assumptions, flags anomalies, and makes recommendations on how to proceed. Isotopes says enterprise customers can deploy the product without sharing their data with the underlying model makers. The startup emerged from stealth and has applied for 10 patents related to its technology. Founders Arun Murthy, Prasanth Jayachandra and Gopal Vijayaraghavan bring prior experience from Hortonworks and Murthy also served as Scale AI’s CTO. The company faces incumbents and other startups in the agentic business analytics space, including Salesforce’s Tableau and WisdomAI.

Participated · Series B · Aug 2025

Seemplicity builds an exposure action platform that automates aggregation, prioritization and remediation workflows to reduce exposure noise and accelerate fixes for security, IT and DevOps teams. The platform consolidates findings, prioritizes the 5% that matters, and automatically creates remediation tasks, claiming a 95% reduction in exposure noise. Seemplicity processes more than 1.5 billion security findings daily and reports an 800% increase in ARR since its Series A alongside 3× growth in new customer acquisition. Founded in 2020 and headquartered in Palo Alto, the company has seen robust Fortune 500 adoption. The new funding will accelerate development and deployment of AI agents that combine each organization’s business logic with external threat intelligence to deliver personalized risk insights and proactive remediation guidance. Seemplicity also plans to scale U.S. operations, expand across the UK and Europe, and drive revenue growth through new sales channels. Seemplicity provides a unified risk-reduction and productivity platform that collects, aggregates and normalizes data from third-party security tools (vulnerability management, appsec, penetration testing, API security and SaaS security) into a single location. The platform enables security teams to build automated workflows that manage findings across multiple tools, aiming to reduce manual remediation work and speed up time-to-remediation. The company claims its automation cuts the time security analysts spend on manual operations by 80% and increases remediation throughput sixfold. Seemplicity positions itself against RBVM and ASOC competitors by focusing on outcomes—reducing time-to-remediation—rather than only consolidating and prioritizing findings. The launch is positioned to help address SOC analyst burnout, with the article citing industry research that more than 70% of SOC analysts experience burnout and 64% say manual work consumes more than half their time. Seemplicity launched the product alongside a $32M funding event to support the platform rollout.

Led · Series A · Oct 2024

Founded in 2023 and headquartered in Mumbai, Neysa provides customized, GPU-first data-center capacity that lets customers train, fine-tune, and deploy AI models locally while meeting latency and data-sovereignty requirements. The company currently runs roughly 1,200 GPUs across facilities in Mumbai, Bengaluru, and Chennai, and plans to scale to more than 20,000 GPUs as demand accelerates. Neysa differentiates itself from hyperscalers by offering highly tailored clusters, round-the-clock support with rapid response times, and a software stack for orchestration, observability, and security. CEO Sharad Sanghi expects capacity to more than triple and revenue to similarly surge over the next year. The startup employs about 110 people and intends to use fresh capital primarily for large-scale GPU deployments, with a smaller share earmarked for R&D and software development. Longer-term, Neysa aims to expand its footprint beyond India as local and global AI labs seek in-country compute.

Participated · Series D · Jun 2024

Eko Health develops AI-enhanced digital stethoscopes and companion software that combine acoustic heart and lung sounds with ECG to aid detection of cardiac conditions. Founded in 2013, the company has sold its stethoscope to more than 500,000 physicians and healthcare providers and has amassed chest-sound and ECG data from millions of patients to train its algorithms. Eko has received FDA clearance for three algorithms, including an April clearance to help detect early signs of heart failure and recent clearance to detect heart murmurs. The company positions its AI to improve the consistency and accuracy of routine exams, bringing cardiology-level assessment to primary care and frontline clinicians. Eko plans to use the new funding to train algorithms to detect pulmonary conditions such as asthma and pneumonia and to expand sales of its device and software outside the U.S. Clinical validation includes a Massachusetts General Hospital study that found Eko’s AI identified more than twice as many patients with heart disease compared to primary care doctors. Eko develops smart stethoscopes and an FDA-cleared AI platform used by hundreds of thousands of healthcare professionals worldwide to detect and monitor heart and lung disease. The company collects phonocardiogram (PCG) and electrocardiogram (ECG) data with its DUO ECG + Digital Stethoscope to train machine-learning algorithms. Eko has partnered with Lifespan Health System’s Cardiovascular Institute to develop an algorithm that detects and stratifies pulmonary hypertension (PH). The goal is an easy-to-deploy, low-cost tool that enables earlier and more accurate identification of PH and improves clinical decision-making. Eko’s work aims to reduce long diagnostic delays and provide a scalable alternative to costly, invasive gold-standard tests. Eko develops digital stethoscopes with features such as noise-canceling, recording, and visualization of heart sounds alongside FDA-cleared clinical support algorithms. In 2020 the FDA granted 510(k) clearance to a suite of Eko algorithms for detecting heart murmurs and atrial fibrillation, and additional clinical results were published in The Journal of the American Heart Association in 2021. The company has launched Eko App, which integrates those algorithms to capture heart sounds and ECG data in the background and provide immediate analysis or summary reports in the exam room. Eko positions this software as a clinical decision support system to help clinicians—particularly in ambulatory and rural primary-care settings—interpret cardiac data. The company is pursuing broader screening for structural heart disease and heart failure, and an independent NHS trial with Mayo Clinic collaborators showed an algorithm could flag LVEF around 40% after 15 seconds of listening, though that algorithm has not yet received FDA clearance for clinical use. Eko plans to commercialize these capabilities and continue product development backed by recent funding. Eko develops a platform that pairs advanced sensors and clinician- and patient-facing software with AI algorithms to elevate detection and monitoring of cardiac and respiratory disease. The company reinvented the stethoscope and introduced a combined handheld digital stethoscope and electrocardiogram (ECG), and its AI analysis is FDA-cleared to help detect heart rhythm abnormalities and structural heart disease. Its FDA-cleared platform is used by tens of thousands of clinicians treating millions of patients around the world, both in-person and via telehealth. Eko has recently launched a telehealth platform and achieved product milestones including clearance of its AI suite. The company plans to expand in-clinic use of its telehealth and AI platform and to launch a home monitoring program for cardiopulmonary patients. Eko is headquartered in Oakland, California and announced new funding to accelerate growth. Eko develops advanced sensors, clinician and patient software, and AI algorithms integrated into a digital stethoscope platform for cardiac and respiratory disease detection and monitoring. The company’s cardiac AI algorithms are cleared by the U.S. Food and Drug Administration and it has launched an AI-powered telehealth platform. Its technology is used by tens of thousands of clinicians, in more than 1,000 institutions worldwide, treating millions of patients. Eko is headquartered in Oakland, California and is privately held. The company has strategic investors including ARTIS Ventures, NTT Venture Capital, DigiTx Ventures, Mayo Clinic, and Sutter Health. Ongoing clinical validation with academic partners is a stated priority to extend cardiologist-level auscultation to general practitioners.